Loading...
•
Jun 30, 2024
Mersana Q2 2024 Earnings Report
Mersana reported continued progress in clinical trials and collaborations, benefiting from reduced operating expenses.
Key Takeaways
Mersana Therapeutics reported financial results for the second quarter ended June 30, 2024. The company is advancing dose escalation in Phase 1 clinical trials of XMT-1660 and XMT-2056 and has made progress in its collaborations. Mersana earned an $8 million development milestone under the Johnson & Johnson collaboration.
Advanced dose escalation in Phase 1 clinical trials of XMT-1660, a Dolasynthen ADC candidate, and XMT-2056, an Immunosynthen ADC candidate.
Made further progress in collaborations with Johnson & Johnson and Merck KGaA, Darmstadt, Germany.
Benefited from efforts to reduce operating expenses.
Initial clinical data readout for XMT-1660 is planned for the second half of 2024.
Mersana
Mersana
Mersana Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com